Remove Events Remove Generic Medicine Remove Pharmaceutical Companies
article thumbnail

Halting Europe’s essential medicines manufacturing exodus

European Pharmaceutical Review

Alarmingly, there are now 93 active ingredients for which no European company holds a certificate. This reliance on sourcing API from other nations puts Europe’s entire manufacturing cycle at risk, especially in the event of global crises and geopolitical tensions.

article thumbnail

What a mild recession could mean for small biotechs in 2023

Pharmaceutical Technology

While the ripple effect of such an event is expected across sectors, in the pharmaceutical arena, small and mid-sized enterprises (SMEs) are predicted to be heavily impacted as the economic downturn affects plans to raise capital, amongst other things. JP Morgan predicts that the US unemployment rate could rise to 4.3%

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Farxiga generic availability, cost, and dosage

The Checkup by Singlecare

While brand-name drugs like Farxiga can be costly, people often want to know: When will a cost-saving generic be available? Is there a generic for Farxiga ? The pharmaceutical company Prasco currently markets a generic version of Farxiga.

Dosage 52
article thumbnail

Why are clinical trials struggling with diversity?

pharmaphorum

Within pharma and healthcare, where greater representation has been proven to lead to better health outcomes for all patients and the pharmaceutical companies developing medicines, change is also happening. As a Non-Clinical Assessor at MHRA he assessed non-clinical data packages for new and generic medicines.

Packaging 143
article thumbnail

Navigating tariffs and diplomacy: the future of India-US pharmaceutical trade

Pharmaceutical Technology

More specifically, the Indian Pharmaceutical Alliance, an organisation representing the country’s largest pharmaceutical companies, has urged the government to reduce import tariffs from the current 10% to zero for pharmaceutical imports from the US.